值得一提的是，今年7月，欧盟委员会正式批准舒格利单抗(商品名：Cejemly)联合含铂化疗用于无EGFR敏感突变, 或无ALK, ROS1, RET基因组肿瘤变异的转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。这是国产PD-L1首度成功出海，也是基石药业全球化布局的关键突破。Foundation Medicine-B (02616) rose by over 9%, as of the time of publication, up 8.59%, at 1.39 Hong Kong dollars, with a turnover of 1.6015 million Hong Kong dollars.
According to the Zhidao Finance APP, Foundation Medicine-B (02616) rose by over 9%, reaching an increase of 8.59% at 1.39 Hong Kong dollars, with a turnover of 1.6015 million Hong Kong dollars.
On the news front, Foundation Medicine released its interim performance for the six months ended June 30, 2024, achieving revenue of 0.254 billion yuan (RMB, the same below). This includes pharmaceutical sales (Afatinib and Pralatinib) of 0.118 billion yuan, licensing revenue of 0.123 billion yuan, and royalties for the use of the Sintilimab franchise of 13.3 million yuan. Gross profit was 0.172 billion yuan, a year-on-year increase of 12.12%; net profit for the period was 15.699 million yuan, turning losses into gains year-on-year. Basic earnings per share were 0.01 yuan.
It is worth mentioning that in July of this year, the European Commission officially approved the use of Sintilimab (trade name: Cejemly) in combination with platinum chemo for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitive EGFR or without ALK, ROS1, RET gene tumor mutations. This marks the first successful international foray of domestically produced PD-L1 and a key breakthrough in the global strategy of Foundation Medicine.
